Level of Asthma Controller Therapy Before Admission to the Hospital  by Belhassen, Manon et al.
Original ArticleLevel of Asthma Controller Therapy Before
Admission to the HospitalManon Belhassen, MSca,b, Carole Langlois, MSca,b, Laurent Laforest, MD, PhDa,b, Alexandra Lelia Dima, PhDc,
Marine Ginoux, MSca,b, Mohsen Sadatsafavi, MD, PhDd,e, and Eric Van Ganse, MD, PhDa,b,f Lyon, France; Amsterdam,
The Netherlands; and British Columbia, Vancouver, CanadaWhat is already known about this topic? Choice of controller therapy and adherence to treatment affect the risk of future
asthma severe exacerbations leading to hospitalization.
What does this article add to our knowledge? Before an asthma-related hospitalization, more than 60% of patients
received little controller therapy and 4% were exposed to unbalanced use of long-acting beta agonists relative to inhaled
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clusters, using Ward’s minimum-variance hierarchical clus-
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COPD- chronic obstructive pulmonary disease
EGB- General Sample of Beneﬁciaries
FDC- ﬁxed-dose combination
GPs- general practitionersICD-10- International Classiﬁcation of Diseases, 10th Revision
ICS- inhaled corticosteroidsLABAs- long-acting beta agonists
LTD- long-term diseaseLTRAs- leukotriene receptor antagonists
OCs- oral corticosteroidsSABAs- short-acting beta agonists
SNIIR-AM- Système National d’Information Inter-Régimes de
l’Assurance MaladieAsthma remains a pivotal public health issue mainly due to
inappropriate use of controllers,1 leading to poor asthma
control,2,3 deteriorated quality of life,4 and high costs for
individuals and society due to medical resource utilization5 and
loss of productivity.6
Preventable factors have been identiﬁed in most asthma
exacerbations and deaths.7 In addition, despite disseminated
guidelines for asthma management8,9 and intensive research on
asthma management in primary care,10 the age-standardized
prevalence rate of uncontrolled asthma, as well as asthma-
related morbidity and mortality, remains high throughout
Europe in all age categories.11 One reason might be the inap-
propriate prescribing and use of asthma medication. Asthma-
related hospitalizations reﬂect severe exacerbation,12 due in part
to inappropriate use of asthma controllers,13,14 and they account
for a noticeable part of medical resource utilization.5,15
The link between the use of inhaled corticosteroids (ICS) and
the occurrence of asthma-related hospitalization has been clearly
established.16-18 A contrario, the part of hospital admissions for
asthma that is due to inappropriate or nonuse of ICS, is little
documented. Investigating health care utilization patterns before
asthma-related hospitalizations is essential for improving the
quality of asthma care services and preventing new occurrences of
severe exacerbation. To provide effective care, services may need
tailoring to different controller use proﬁles.
The General Sample of Beneﬁciaries (EGB; 1/97th random
sample of national primary and secondary care claims data) offers
a snapshot of disease management in real-life conditions, for
example, from recorded drug dispensations and outcomes such as
hospital admissions due to severe exacerbations.19-21 The aim of
the present study was to use these data to investigate the patterns
of use of asthma medication, so as to distinguish one or more
therapeutic proﬁles of patients who end up being admitted to
hospitals.
METHODS
This was a population-based study of a cohort of patients iden-
tiﬁed from the EGB database, a 1/97th representative random
sample of the Système national d’information inter-régimes de
l’Assurance maladie (SNIIR-AM),19-21 a French nationwide
population-based record of individual and anonymized data on all
reimbursements for health care utilization, including therapy and
outpatient medical and nursing care. No direct information on the
medical indication is linked with each reimbursement, but the
SNIIR-AM includes information on long-term disease (LTD) statuscoded in International Classiﬁcation of Diseases, 10th Revision
(ICD-10) codes. LTD status allows patients to receive treatment for
severe and costly conditions without out-of-pocket payment. SNIIR-
AM also contains information on free-access-to-care status, which
enables patients of lower socioeconomic status to receive free medical
care. Information from the SNIIR-AM database and medical
information from the French hospital discharge database (Pro-
gramme de Médicalisation des Systèmes d’Information) about all
patients admitted to hospital in France, including discharge
diagnoses coded in ICD-10 codes, medical procedures, and French
diagnosis-related groups, are cross-referenced.
This observational study was conducted on anonymized data, and
the National Informatics and Liberty Committee has delivered an
overall authorization to use EGB data for research purposes. This
study was performed after approval by the French Institute for
Health Data (Institut des Données de Santé, approval no. 94,
September 9, 2014).
Study population
Subjects were eligible for inclusion in the cohort if, between 2006
and 2014, they ﬁlled at least 3 dispensations for asthma-related
medications (all R03 Anatomical Therapeutic Chemical codes
except R03DX05, R03AC18, R03BB04, R03BB01, R03AK03, and
R03AK04) and if the patients were aged between 6 and 40 years at
the third dispensation. These drugs were excluded because they were
used for more severe asthma (omalizumab) managed by secondary
care physicians, or not used for asthma in France at the time of the
study (indacaterol, tiotropium, ipratropium), or not available in
France (reproterol or salbutamol and cromoglicate) within any
period of 12 successive months. Patients who suffered from chronic
obstructive pulmonary disease were excluded on the basis of LTD
status and/or hospitalizations (ICD-10 codes J41, J42, J44, and
J961), or on the dispensation of tiotropium bromide (R03BB04
Anatomical Therapeutic Chemical code). Likewise, patients with
cystic ﬁbrosis were excluded (E84 ICD-10 code). So were patients
receiving omalizumab (R03DX05 Anatomical Therapeutic Chemi-
cal code) because their asthma is mostly managed in secondary care
by respiratory physicians. For each patient, we deﬁned the entry date
as the date of the third dispensation of respiratory medications that
resulted in case identiﬁcation. Within the cohort, we selected
patients who experienced asthma-related hospitalization, deﬁned as a
hospital discharge with asthma (J45 and J46 ICD-10 codes) as
primary or related reason for hospitalization. The date of the ﬁrst
asthma-related hospitalization was deﬁned as the index date. In line
with similar studies,16,22 we requested at least a 12-month baseline
period between the entry date and the index date, during which
patients with asthma-related hospitalization were excluded to ensure
that there were sufﬁcient longitudinal data to assess drugs received
before the index date. If a patient had more than 1 asthma-related
hospitalization, only the ﬁrst one since the entry date was used for
the analyses.
ANALYSIS
All analyses were performed in SAS V.9.3 (SAS Institute,
Carry, NC). Subjects were categorized by an unsupervised clas-
siﬁcation algorithm that classiﬁed patients on the basis of
controller therapy recorded, that is, ICS in a single canister, long-
acting beta agonists (LABAs) in a single canister, or ﬁxed-dose
combinations (FDCs) of LABAs and ICS. Drug use was
assessed in the 12 months before the index date, even if patients
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FIGURE 1. Flow chart. Between 2006 and 2014, we identified 73,692 patients with 3 or more dispensations for asthma-related
medications during any 12-month period. Among selected patients, 30.6% were aged 6 to 40 years at the third dispensation. We
excluded 259 patients with COPD, 27 patients with CF, and 5 patients taking omalizumab. We finally selected 275 patients (1.5%) with
asthma-related hospitalization of 12 months or more after the entry date. CF, Cystic fibrosis; COPD, chronic obstructive pulmonary
disease.
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formed using an agglomerative (bottom-up) approach, and
Ward’s linkage using 3 numerical variables (number of units of
LABAs alone, ICS alone, and FDCs of LABAs þ ICS) to cate-
gorize patients on drug received in the 12 months before the
index date. With this algorithm, every possible cluster combi-
nation is considered at each step of agglomerative hierarchical
clustering, and samples are merged into larger clusters to mini-
mize the within-cluster sum of squares and to maximize thebetween-cluster sum of squares. To compare the clusters,
ANOVA, Kruskal-Wallis, and chi-square tests were used. Ward’s
method is a widely used algorithm that minimizes the variance
within clusters.23,24 In Ward’s minimum-variance method, the
distance between 2 clusters is the ANOVA sum of squares be-
tween the 2 clusters added up over all the variables. At each
generation, the within-cluster sum of squares is minimized over
all partitions obtainable by merging 2 clusters from the previous
generation. The sums of squares are easier to interpret when they
TABLE I. Subjects’ characteristics and treatment dispensed before asthma-related hospitalization (n ¼ 275)
Characteristics or medications
Patients with asthma-related hospitalization (n [ 275)
n (%) Mean – SD
Age (y) — 19.0  11.7
Sex: Female 130 (47.3) —
LTD status for asthma* 34 (12.4) —
Free-access-to-care status 63 (22.9) —
Variables ascertained in the 12-mo period before the index date
Dispensations of FDCs of ICS þ LABAs 155 (56.4) 5.1  4.3
Dispensations of ICS alone 104 (37.8) 2.9  2.5
Dispensations of LABAs alone 30 (10.9) 4.3  3.4
Visits to GP 240 (87.3) 7.0  6.3
Visits to lung specialist or pediatrician 46 (16.7) 2.3  2.7
Outpatient visits (all specialists) 148 (53.8) 3.5  4.1
Variables ascertained in the 3-mo period before the index date
Dispensations of SABAs 178 (64.7) 2.5  1.9
Dispensations of LTRAs 70 (25.5) 1.8  0.9
Dispensations of OCs 121 (44.0) 1.8  1.3
*Allows patients to receive treatment for severe and costly conditions without out-of-pocket payment.
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variance (squared semipartial correlations). SAS procedures
CLUSTER and TREE were used for the cluster analysis and
illustration.
The following variables were explored as illustrative variables:
age at entry date, number of visits to general practitioners (GPs),
lung specialists, pediatricians, and other specialists in the
12 months before the index date, and the number of dispensa-
tions of short- acting beta agonists (SABAs), leukotriene receptor
antagonists (LTRAs), and oral corticosteroids (OCs) during the
3-month period before the index date. For dispensations of these
drug classes, the time window was shortened to 3 months
because of the short duration of action of these therapies. The
quantitative variables were described as mean and SD and the
categorical variables as frequencies and percentages. All analyses
were conducted with an alpha level of 5%.
RESULTS
Between 2006 and 2014, we identiﬁed 73,692 patients with
3 or more dispensations for asthma-related medications during
any 12-month period, corresponding to 11.3% of the French
population recorded in the EGB between 2006 and 2014.
Among selected patients, 22,586 (30.6%) were aged 6 to 40
years at the third dispensation. We excluded 259 patients (1.1%)
with chronic obstructive pulmonary disease, 27 patients (0.1%)
with cystic ﬁbrosis, and 5 patients (0.02%) with dispensation of
omalizumab. Among 17,846 remaining patients with at least
12 months of follow-up data available before and after the entry
date, we ﬁnally selected 275 patients (1.5%) with asthma-related
hospitalization of 12 months or more after the entry date
(Figure 1).
Description of patients with asthma-related
hospitalization
Themean age at cohort entry was 19.0 11.7 years, and 47.3%
of the subjects were women. Aminority of subjects beneﬁted from
LTD status for asthma (12.4%) and patients with free-access-to-
care status represented 22.9% of the cohort. Patients’characteristics are provided in Table I. About 87% of patients had
at least 1 contact with aGP, while 16%had at least 1 contact with a
lung specialist or a pediatrician during the study period.During the
12 months before the index date, FDCs were dispensed to 56.4%
of patients; 37.8% of patients received ICS in a single canister and
10.9% received LABAs in a single canister. During the 3 months
preceding the index date, SABAs and OCs were dispensed to
64.7% and 44.0% of patients, respectively.
Treatment profiles before asthma-related
hospitalization
Three different treatment proﬁles (clusters) appeared from the
classiﬁcation of the 275 patients hospitalized for asthma. One
hundred seventy-ﬁve patients (63.6%) were identiﬁed in cluster
1, 89 patients (32.4%) in cluster 2, and 11 patients (4.0%) in
cluster 3. The clusters characteristics are summarized in Table II.
No difference was observed between the 3 clusters in terms of age
(P ¼ .32), sex (P ¼ .36), or free-access-to-care status (P ¼ .40).
Conversely, patients from cluster 1 were less likely to beneﬁt
from LTD status (5.7%) than patients from clusters 2 (23.6%)
and 3 (27.3%) (P < .0001).
In the 12 months preceding hospitalization, patients from
cluster 1 had low levels of dispensation of controller medication,
that is, ICS in a single canister (mean of 1.2 units dispensed),
LABAs in a single canister (mean of 0.2 units dispensed), or FDCs
(mean of 0.6 units dispensed). Cluster 2 patients primarily received
FDCs (mean of 7.5 units dispensed) (P < .0001), whereas cluster
3 patients received free combinations of ICS (mean of
5.4 units dispensed) and LABAs (mean of 8.2 units dispensed)
(P< .0001), with on average 50%more reﬁlls for LABAs than for
ICS. Cluster proﬁles are graphically displayed in Figure 2.
Patients from cluster 1 had fewer visits to the GP (mean ¼ 5.3
visits) in the 12 months preceding hospitalization than those
from cluster 2 (mean of 7.7 visits) or cluster 3 (mean of 6.2
visits). No differences were observed regarding visits to lung
specialists or to pediatricians (P ¼ .60). Last, patients from
cluster 1 had fewer dispensations of SABAs (P ¼ .01) and LTRAs
(P < .0001) than patients from clusters 2 and 3 during the
FIGURE 2. Clusters of patients before asthma-related hospitalization (n ¼ 275). A, Dendrogram: The vertical axis represents the distance
or dissimilarity between clusters. The horizontal axis represents the patients. Each joining (fusion) of 2 clusters is represented on the
graph by the splitting of a vertical line into 2 vertical lines. The vertical position of the split, shown by the short horizontal bar, gives the
distance (dissimilarity) between the 2 clusters. B, Cluster plot: The vertical axis and the horizontal axis represent the canonical variables 1
and 2. Hierarchical clustering is based on the core idea of objects being more related to nearby objects than to objects farther away. These
algorithms connect “objects” to form “clusters” on the basis of their distance. A cluster can be described largely by the maximum
distance needed to connect parts of the cluster.
TABLE II. Characteristics of the clusters (n ¼ 275)
Characteristic, n (%) Cluster 1 (n [ 175) Cluster 2 (n [ 89) Cluster 3 (n [ 11) P value
Age (y) 18.3 (11.5) 19.9 (12.0) 22.2 (12.1) .32
Sex: Female 85 (48.6) 38 (42.7) 7 (63.6) .36
LTD status for asthma 10 (5.7) 21 (23.6) 3 (27.3) <.0001
Free-access-to-care status 44 (25.1) 16 (18.0) 3 (27.3) .40
Variables ascertained in the 12-mo period before the index date, mean  SD
Dispensations of FDCs of ICS þ LABAs 0.6  1.0 7.5  4.1 1.0  1.9 <.0001
Dispensations of ICS alone 1.2  2.0 0.3  0.8 5.4  4.2 <.0001
Dispensations of LABAs alone 0.2  0.8 0.0  0.3 8.2  1.7 <.0001
Visits to GP 5.3  4.9 7.7  8.5 6.2  3.4 .02
Visits to lung specialist or pediatrician 0.3  0.7 0.6  2.2 0.2  0.6 .60
Outpatient visits (all specialists) 1.8  3.7 2.0  3.2 1.9  2.7 .35
Variables ascertained in the 3-mo period before the index date
Dispensations of SABAs 1.3  1.7 2.1  2.2 2.1  1.8 .01
Dispensations of LTRAs 0.3  0.6 0.8  1.1 1.0  1.6 <.0001
Dispensations of OCs 0.7  1.0 1.2  1.7 0.3  0.5 .05
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than did clusters 1 and 2 (P ¼ .05).DISCUSSION
In this study, using primary and secondary care data, we iden-
tiﬁed 3 distinct asthma treatment clusters before hospital admis-
sion for asthma, using an unsupervised learning algorithmbased on
controllers dispensed during the 12 months preceding hospitali-
zation. The ﬁrst cluster (63.6%) had very low dispensation of
controller therapy, with around 1 reﬁll of ICS, LABAs, or FDCs in
12 months. This cluster also had little dispensation of other
treatments (SABAs, LTRAs, and OCs). The second cluster
(32.4%) included patients with high use of FDCs (mean of 7.5
units in the 12 months preceding hospitalization) and SABAs,
OCs, and LTRAs. These patients frequently visited GPs (7.7 visitsin 12 months). The last group (4.0%) included patients with non-
FDCs of ICS and LABAs, with higher use of LABAs (8.2 reﬁlls)
than of ICS (5.4 reﬁlls). This cluster was also characterized by
common free-access-to-care status and LTD status for asthma.
Patients from cluster 1 were constantly untreated, be it with
controller therapy during the full 12-month period preceding
hospitalization, or with SABAs, LTRAs, or OCs during the 3
months before hospitalization. Underuse of controller therapy,
especially ICS, has been highlighted by many studies16 as a major
issue in asthma management. A recent meta-analysis, focused on
the risk of asthma exacerbation after stopping low-dose ICS,
concluded that patients with well-controlled asthma who stop
regular use of low-dose ICS have an increased risk of exacerba-
tion compared with those who continue ICS.25 The high per-
centage of free-access-to-care status (25%, while the median
coverage is around 8.6% in the overall population26 and 11.8%
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status, possibly linked with lower health literacy, which could
contribute to the inappropriate management of asthma.27-29 In
contrast, the low frequency of LTD status suggests that asthma
was not recognized as being of high severity. In theory, acute
asthma attacks could be included in this cluster because few
SABAs and OCs were dispensed before hospitalization. We
accepted SABAs to be used as sole respiratory drugs for inclusion
(so not forcing the dispensing of at least 1 controller drug among
the 3 respiratory treatments leading to inclusion) because asthma
severity may be underestimated by prescribers who do not
initiate controller therapy while it is needed, or by patients who
do not acquire prescribed controller therapy. However, hospi-
talization is less preventable in this group, as the absence of
controller therapy suggests intermittent asthma, at lower risk for
adverse outcomes than persistent asthma. Information on
symptoms and airﬂow limitation would have allowed character-
ization of persistent asthma and asthma severity, but these vari-
ables are not recorded in the database. Altogether, these data
suggest a population of more deprived patients, not appropriately
managed for their asthma, possibly poor perceivers of broncho-
constriction, and possibly with rapidly deteriorating asthma.
Patients from cluster 2 had regular controller therapy (FDCs),
besides OCs and SABAs, and relatively more frequent medical
contacts. Furthermore, the high frequency of free-access-to-care
status (18%) and the high percentage of LTD status (27%)
suggest more severe and not well-controlled asthma, possibly
with poor quality of use of inhalers.30,31
Finally, cluster 3 had high percentage of free-access-to-care
status (27%), common LTD status for asthma (27%), and few
contacts with specialists, again suggesting a more deprived
population, with poor quality of care, and possibly low health
literacy. Despite the absence of evidence of serious risk led by the
use of LABAs associated with ICS in randomized controlled
trials, likely due to infrequent occurrence of adverse events, the
issue of safety of LABAs remains a matter of debate.32 Evidence
is also limited in the observational context. A recent systematic
review assessing the risk of LABAs associated with ICS,
compared with ICS alone, did not indicate any increased risk for
emergency department visits or hospital admissions.33 However,
no reliable conclusions could be reached for children, or for
potential differences between LABAs associated with ICS, in
FDCs, and in 2 separate canisters, due to a lack of data.32
Some limitations must be acknowledged. Although the
SNIIR-AM exhaustively records all reimbursed health care uti-
lization in the covered population, patients with asthma needed
to be identiﬁed from age, comorbidities, and asthma medication
dispensations because of the absence of diagnostic codes.22,34,35
Precautions were, however, taken to include patients likely to
suffer from persistent asthma, with the requirement of at least 3
dispensations of R03 over 12 months in a recent period. In
addition, young children (aged <6 years), adults older than 40
years (to avoid including those with chronic obstructive pul-
monary disease), and patients with cystic ﬁbrosis were excluded.
Consequently, our study was performed with a cohort that was
highly likely to include patients with persistent asthma. Actually,
the prevalence of asthma in our study was comparable to the
prevalence observed in other studies,36 supporting the validity of
our identiﬁcation algorithm. Additional limitations were the
absence of information in the SNIR-AM on lung function or the
therapy that was actually prescribed by health care providers.In this study, treatment clusters were identiﬁed only in hos-
pitalized patients, but different phenotypes based on medication
utilization could possibly be identiﬁed in all patients (hospital-
ized or not). Indeed, it would have been desirable to compare
ﬁndings in the hospitalized cohort to ﬁndings in a control group
of patients who were not hospitalized. It was, however, not
possible to identify a valid control group in this study because
asthma discharge diagnoses were speciﬁcally used to identify cases
with maximal validity, which would not be true for nonhospi-
talized controls, for whom equivalent diagnostic data would be
mostly missing. Another potential marker of asthma, acute dis-
pensings of OCs, would not be as reliable as a hospital discharge
diagnosis because OCs may be used for several indications
beyond asthma. This study should also be replicated using larger
sample sizes, targeting populations at high risk, such as patients
who experienced near-fatal asthma exacerbation or death.
Furthermore, in our study, dispensation of controller therapy was
evaluated in the 12 months before the hospitalization. However,
in severe acute asthma, exacerbation could happen quickly, and
precise information on drug use during the shorter time span
before exacerbation could be more informative. Furthermore,
clinical variables might be added to the hierarchical clustering
method to better characterize proﬁles of patients. Also, data are
not capturing “use,” but dispensing as a surrogate for use.
A linkage between data from ﬁeld studies and data from Social
Security claims could provide clinical variables and information
on adherence or quality of inhalers use, for instance.
The results of this study are important because they revealed
distinct patterns of use of therapy before hospitalization due to
asthma, in longitudinal data sets with information on socioeco-
nomic status. In our study, asthma therapy was clearly inappro-
priate in two-third of patients (clusters 1 and 3), conferring
considerable risk of exacerbation. Because of the selection criteria
applied, these results can be generalized to patients with persistent
asthma. There are many plausible ways to improve the identiﬁed
care gap in asthma. Clinicians could improve the quality of pre-
scribing,37 and patients should be informed on appropriate use of
therapy14 and technical use of inhalers.30 Clinicians should be
informed on the actual controller use of their patients, for
example, via feedback from claims data or from consulting practice
prescribing records. Personal action plans should be written,
describing how patients may recognize deterioration in their
asthma and what steps they should take to reestablish control.9
Other clinical health care providers (eg, nurses) could also re-
view the use of therapy and provide training and support to pa-
tients.38 Policymakers should develop actions targeting both
clinicians (eg, via asthma audits) and patients (eg, by providing
ways for patients to have direct contacts with advisors, eg, using
information technology, or through pharmacies).
In conclusion, we observed that most French patients with
asthma were not exposed to controllers before an asthma-related
hospitalization, while 4% were exposed to higher dispensation of
LABAs than of ICS. Investigating these patterns in detail may
lead to concrete measures to prevent exacerbations. Educational
interventions and close monitoring at the population level are
deemed necessary to reduce the asthma-associated exacerbation.REFERENCES
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